Awards with collaborative funding partners

The Approved Funds represents the current award amount under agreement with the grantee which can be less the amount approved by the governing board. For projects approved by the governing that have not yet been issued an award agreement, the Approved Funds will temporarily reflect the amount approved by the governing board.
Collaborative Funder RFA Approved funds
Victoria, Australia Early Translational I Developmental Candidates for Cell-Based Therapies for Parkinson's Disease (PD) $5,190,752
Maryland Early Translational II Neural restricted, FAC-sorted, human neural stem cells to treat traumatic brain injury $1,517,767
Germany Early Translational II Developing a therapeutic candidate for Canavan disease using induced pluripotent stem cell $1,835,983
Maryland Early Translational II Banking transplant ready dopaminergic neurons using a scalable process $4,998,871
Germany Early Translational II Bone Marrow Mesenchymal Stem Cells to Heal Chronic Diabetic Wounds $4,635,576
Germany Early Translational II Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication $2,756,536
Germany Early Translational II Crosstalk: Inflammation in Parkinson’s disease (PD) in a humanized in vitro model $2,472,839
Canada Disease Team Research I Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) $19,999,826
Germany Disease Team Research I Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke $20,000,000
Canada Disease Team Research I THERAPEUTIC OPPORTUNITIES TO TARGET TUMOR INITIATING CELLS IN SOLID TUMORS $19,979,660
UK Disease Team Research I Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells $18,759,276
JDRF Disease Team Research I Cell Therapy for Diabetes $22,999,933
UK Disease Team Research I Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) $18,904,916
Victoria, Australia Early Translational I Neural Stem Cells as a Developmental Candidate to Treat Alzheimer Disease $3,599,997
Victoria, Australia Early Translational I Ensuring the safety of cell therapy: a quality control pipeline for cell purification and validation $5,830,771
Victoria, Australia Early Translational I Methods for detection and elimination of residual human embryonic stem cells in a differentiated cell product $5,405,397
Germany Early Translational I Using patient-specific iPSC derived dopaminergic neurons to overcome a major bottleneck in Parkinson's disease research and drug discovery $3,698,646
Japan Basic Biology II Role of the microenvironment in human iPS and NSC fate and tumorigenesis $1,256,194

© 2013 California Institute for Regenerative Medicine